On June 24, 2022, Axsome Therapeutics, Inc. received from the U.S. Food and Drug Administration (the FDA) proposed labeling for the Company's AXS-05 product candidate with respect to its New Drug Application (the NDA) for AXS-05 for the treatment of major depressive disorder. The Company is reviewing the proposed labeling and will reply to the FDA to secure final labeling agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.8 USD | +0.82% | +4.31% | -6.02% |
30/04 | North American Morning Briefing : More Earnings -2- | DJ |
29/04 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.02% | 3.55B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B | |
-4.33% | 8.5B |
- Stock Market
- Equities
- AXSM Stock
- News Axsome Therapeutics, Inc.
- Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration